Predictive Value of Glypican-1 in Pancreatic Ductal Adenocarcinoma

In a recent study, researchers investigated the value of serum exosomal and serum glypican 1 (GPC-1) in predicting diagnosis and prognosis of early-stage pancreatic ductal adenocarcinoma (PDAC). According to the authors, exosomal and serum GPC-1 could differentiate early-stage PDAC samples from healthy controls, but not from chronic pancreatitis (CP) or benign pancreatic tumor (BPT) samples. The findings were published in Frontiers in Oncology.

The study included serum samples from 50 patients with PDAC, 6 patients with BPT, 9 patients with CP, and 50 healthy controls. Researchers isolated serum exosomes with an exosome isolation kit and measured exosomal and serum GPC-1 expression levels using enzyme-linked immunosorbent assay (ELISA). The investigators also performed a freeze-thaw process to identify the stability of GPC-1.

Glypican-1 Shows Predictive Value in PDAC

Reportedly, the average concentrations of serum exosomal and serum GPC-1 were 1.5 and 0.8 ng/ml, respectively. The authors noted that GPC-1 expression levels were stable throughout repeated freezing and thawing (P>.05).

Serum exosomal and serum GPC-1 levels were significantly higher in patients with PDAC compared with healthy controls (P<.0001), but were only slightly higher versus those in observed in CP and BPT (P>.05). Additionally, expression levels remained elevated in PDAC, CP, and BPT 5 days after pancreatic surgery (P<.05).

Notably, the researchers found that patients with high levels of exosomal (P=.006) and serum (P=.010) GPC-1 had reduced relapse-free survival. The team’s multivariate analyses determined that serum exosomal (P=.008) and serum (P=.041) GPC-1 were independent predictive factors for early PDAC relapse.

Ultimately, the authors concluded that “serum exosomal and serum GPC-1 expression levels were independent predictors of early recurrence and metastasis for early-stage PDAC after surgery.”

Read More Recent Studies on the Pancreatic Cancer Resource Center